Nuclear Receptor Superfamily

Venue: Wyndham Newark Airport

Location: Newark, New Jersey, United States

Event Date/Time: Sep 29, 2003 End Date/Time: Sep 30, 2003
Report as Spam

Description

Over the past decade, a much more complete understanding of the complexity of classical nuclear hormone receptor signaling has emerged. This growing knowledge serves as a basis for revitalizing drug discovery approaches for these “old targets.” In particular, the finding that multiple signaling mechanisms can underlie nuclear receptor-mediated physiology, and that nuclear receptor ligands act through these mechanisms selectively, and in a tissue-specific manner, makes the notion of side-effect free nuclear receptor therapeutics seem like a distinct possibility. Learn from leading pharmaceutical industry experts and take the opportunity to discuss new research with the experts.

PARTICIPANTS INCLUDE:

AstraZeneca
Bayer Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly & Company
Incyte San Diego
J&J Pharmaceutical R&D
Karo Bio USA
Locus Pharmaceuticals
Merck Research Labs
National Cancer Institute
National Institutes of Health
Panvera Corporation
Pfizer Global R&D
Sangamo Biosciences
Schering Plough
Van Andel Research Institute
X-Ceptor Therapeutics


KEYNOTE PRESENTATIONS:

The Human Glucocorticoid Receptor: Molecular Mechanisms Controlling the Termination of Glucocorticoid Responses
John A. Cidlowski, Ph.D., Chief of Laboratory of Signal Transduction
NATIONAL INSTITUTES OF HEALTH

Vitamin D Receptor: A Drug Discovery Target of the Nuclear Receptor Superfamily
Sunil Nagpal, Ph.D., Group Leader, Gene Regulation Bone Research & Enabling Technology
ELI LILLY & COMPANY

Venue